SEC Filing | Amgen Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 1999 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-12477 AMGEN INC. (Exact name of registrant as specified in its charter) Delaware 95-3540776 - ------------------------------- ----------------------------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, Thousand Oaks, California 91320-1799 - ---------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (805) 447-1000 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No As of September 30, 1999, the registrant had 1,021,515,626 (A) shares of Common Stock, $.0001 par value, outstanding. - ------------ (A) All share numbers have been retroactively adjusted to reflect a two-for-one split of the common stock to be effected in the form of a 100 percent stock dividend to be distributed on November 19, 1999 to stockholders of record on November 5, 1999.

AMGEN INC. INDEX Page No. PART I FINANCIAL INFORMATION Item 1. Financial Statements.................................... 3 Condensed Consolidated Statements of Operations - three and nine months ended September 30, 1999 and 1998.............................. 4 Condensed Consolidated Balance Sheets - September 30, 1999 and December 31, 1998....................... 5 Condensed Consolidated Statements of Cash Flows - nine months ended September 30, 1999 and 1998.............................. 6 Notes to Condensed Consolidated Financial Statements..................................................... 7 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.............................................. 13 PART II OTHER INFORMATION Item 1. Legal Proceedings........................................ 25 Item 6. Exhibits and Reports on Form 8-K......................... 26 Signatures....................................................... 27 Index to Exhibits................................................ 28 2

PART I - FINANCIAL INFORMATION Item 1. Financial Statements The information in this report for the three and nine months ended September 30, 1999 and 1998 is unaudited but includes all adjustments (consisting only of normal recurring accruals, unless otherwise indicated) which Amgen Inc. ("Amgen" or the "Company") considers necessary for a fair presentation of the results of operations for those periods. The condensed consolidated financial statements should be read in conjunction with the Company's financial statements and the notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December 31, 1998. Interim results are not necessarily indicative of results for the full fiscal year. 3

AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 1999 1998 1999 1998 -------------- --------------- ----------------- --------------- Revenues: Product sales $ 769.2 $ 641.8 $2,195.4 $1,819.8 Corporate partner revenues 43.6 38.4 119.6 90.9 Royalty income 34.4 20.7 98.2 52.5 -------------- --------------- ----------------- --------------- Total revenues 847.2 700.9 2,413.2 1,963.2 -------------- --------------- ----------------- --------------- Operating expenses: Cost of sales 98.9 87.2 290.1 250.1 Research and development 198.4 166.0 580.5 470.9 Selling, general and administrative 159.9 134.2 450.0 369.3 Loss of affiliates, net 3.3 4.3 15.3 20.7 Legal award (49.0) - (49.0) - -------------- --------------- ----------------- --------------- Total operating expenses 411.5 391.7 1,286.9 1,111.0 -------------- --------------- ----------------- --------------- Operating income 435.7 309.2 1,126.3 852.2 Other income (expense): Interest and other income 22.0 16.1 65.0 55.2 Interest expense, net (4.9) (3.2) (10.4) (8.7) -------------- --------------- ----------------- --------------- Total other income (expense) 17.1 12.9 54.6 46.5 -------------- --------------- ----------------- --------------- Income before income taxes 452.8 322.1 1,180.9 898.7 Provision for income taxes 152.8 101.1 366.1 274.1 -------------- --------------- ----------------- --------------- Net income $ 300.0 $ 221.0 $ 814.8 $ 624.6 ============== =============== ================= =============== Earnings per share: Basic $ 0.29 $ 0.22 $ 0.80 $ 0.61 Diluted $ 0.28 $ 0.21 $ 0.76 $ 0.59 Shares used in calculation of earnings per share: Basic 1,021.5 1,020.4 1,022.1 1,020.6 Diluted 1,078.8 1,059.9 1,078.0 1,055.9 See accompanying notes. 4

AMGEN INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except per share data) (Unaudited) September 30, December 31, 1999 1998 ------------- ------------- ASSETS Current assets: Cash and cash equivalents $ 188.3 $ 201.1 Marketable securities 1,335.7 1,074.9 Trade receivables, net 300.4 319.9 Inventories 146.9 110.8 Other current assets 155.1 156.6 ----------------- ------------------ Total current assets 2,126.4 1,863.3 ----------------- ------------------ Property, plant and equipment at cost, net 1,508.9 1,450.2 Investments in affiliated companies 127.1 120.9 Other assets 274.4 237.8 ----------------- ------------------ $4,036.8 $3,672.2 ================= ================== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 100.8 $ 121.6 Commercial paper 99.7 99.7 Accrued liabilities 617.8 659.7 Current portion of long-term debt - 6.0 ----------------- ------------------ Total current liabilities 818.3 887.0 Long-term debt 223.0 223.0 Contingencies Stockholders' equity: Preferred stock: $.0001 par value; 5 shares authorized; none issued or outstanding - - Common stock and additional paid-in capital; $.0001 par value; 1,500 shares authorized; outstanding - 1,021.5 shares in 1999 and 1,018.5 shares in 1998 1,984.0 1,671.9 Retained earnings 1,036.3 894.3 Accumulated other comprehensive loss (24.8) (4.0) ----------------- ------------------ Total stockholders' equity 2,995.5 2,562.2 ----------------- ------------------ $4,036.8 $3,672.2 ================= ================== See accompanying notes. 5

AMGEN INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In millions) (Unaudited) Nine Months Ended September 30, 1999 1998 -------------- --------------- Cash flows from operating activities: Net income $ 814.8 $ 624.6 Depreciation and amortization 128.6 108.2 Other non-cash expenses - 4.5 Gain on sale of investment - (13.2) Loss of affiliates, net 15.3 20.7 Cash provided by (used in): Trade receivables, net 19.5 (27.3) Inventories (36.1) 0.1 Other current assets 4.6 (22.3) Accounts payable (20.8) (16.6) Accrued liabilities (41.9) 74.1 -------------- --------------- Net cash provided by operating activities 884.0 752.8 -------------- --------------- Cash flows from investing activities: Purchases of property, plant and equipment (211.3) (320.0) Proceeds from maturities of marketable securities 25.9 12.1 Proceeds from sales of marketable securities 545.4 346.7 Purchases of marketable securities (847.8) (580.5) Other (3.0) 15.3 -------------- --------------- Net cash used in investing activities (490.8) (526.4) -------------- --------------- Cash flows from financing activities: Increase in commercial paper - 99.6 Repayment of long-term debt (6.0) (30.0) Net proceeds from issuance of common stock upon the exercise of stock options 201.7 223.3 Tax benefits related to stock options 110.4 52.5 Repurchases of common stock (672.8) (692.8) Other (39.3) (14.0) -------------- --------------- Net cash used in financing activities (406.0) (361.4) -------------- --------------- Decrease in cash and cash equivalents (12.8) (135.0) Cash and cash equivalents at beginning of period 201.1 239.1 -------------- --------------- Cash and cash equivalents at end of period $ 188.3 $ 104.1 ============== =============== See accompanying notes. 6

AMGEN INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 1999 1. Summary of significant accounting policies Business Amgen Inc. ("Amgen" or the "Company") is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology. Principles of consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as well as affiliated companies for which the Company has a controlling financial interest and exercises control over their operations ("majority controlled affiliates"). All material intercompany transactions and balances have been eliminated in consolidation. Investments in affiliated companies which are 50% or less owned and where the Company exercises significant influence over operations are accounted for using the equity method. All other equity investments are accounted for under the cost method. The caption "Loss of affiliates, net" includes Amgen's equity in the operating results of affiliated companies and the minority interest others hold in the operating results of Amgen's majority controlled affiliates. Inventories Inventories are stated at the lower of cost or market. Cost is determined in a manner which approximates the first-in, first-out (FIFO) method. Inventories are shown net of applicable reserves and allowances. Inventories consist of the following (in millions): September 30, December 31, 1999 1998 ----------------- ----------------- Raw materials $ 29.8 $ 18.1 Work in process 78.0 49.1 Finished goods 39.1 43.6 ----------------- ----------------- $146.9 $110.8 ================= ================= 7

Product sales Product sales primarily consist of sales of EPOGEN(R) (Epoetin alfa) and NEUPOGEN(R) (Filgrastim). The Company has the exclusive right to sell Epoetin alfa for dialysis, diagnostics and all non-human uses in the United States. The Company sells Epoetin alfa under the brand name EPOGEN(R). Amgen has granted to Ortho Pharmaceutical Corporation (which has assigned its rights under the product license agreement to Ortho Biotech, Inc.), a subsidiary of Johnson & Johnson ("Johnson & Johnson"), a license relating to Epoetin alfa for sales in the United States for all human uses except dialysis and diagnostics. Pursuant to this license, Amgen does not recognize product sales it makes into the exclusive market of Johnson & Johnson and does recognize the product sales made by Johnson & Johnson into Amgen's exclusive market. Sales in Amgen's exclusive market and adjustments thereto are derived from Company shipments and from third-party data on shipments to end users and their usage (see Note 6, "Contingencies - Johnson & Johnson arbitrations"). Sales of the Company's other products are recognized when shipped. Foreign currency transactions The Company has a program to manage foreign currency risk. As part of this program, it has purchased foreign currency option and forward contracts to hedge against possible reductions in values of certain anticipated foreign currency cash flows generally over the next 12 months, primarily resulting from its sales in Europe. At September 30, 1999, the Company had option and forward contracts to exchange foreign currencies for U.S. dollars of $73.5 million and $10.8 million, respectively, all having maturities of eight months or less. The option contracts, which have only nominal intrinsic value at the time of purchase, are designated as effective hedges of anticipated foreign currency transactions for financial reporting purposes and accordingly, the net gains on such contracts are deferred and recognized in the same period as the hedged transactions. The forward contracts do not qualify as hedges for financial reporting purposes and accordingly, are marked-to-market. Net gains on option contracts (including option contracts for hedged transactions whose occurrence are no longer probable) and changes in market values of forward contracts are reflected in "Interest and other income". The deferred premiums on option contracts and fair values of forward contracts are included in "Other current assets". The Company has additional foreign currency forward contracts to hedge exposures to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies. At September 30, 1999, the Company had forward contracts to exchange foreign currencies for U.S. dollars of $37.6 million, all having maturities of less than three months. These contracts are designated as effective hedges and accordingly, gains and losses on these forward contracts are recognized in the same period the offsetting gains and losses of hedged assets and liabilities are realized and recognized. The fair values of the forward contracts are included in the corresponding captions of the hedged assets and 8

liabilities. Gains and losses on forward contracts, to the extent they differ in amount from the hedged assets and liabilities, are included in "Interest and other income". In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards ("SFAS") No. 133, "Accounting for Derivative Instruments and Hedging Activities". The date required for adoption of this statement has been delayed until fiscal years beginning after June 15, 2000. Because of the Company's minimal use of derivatives, management anticipates that the adoption of this new statement will not have a significant effect on earnings or the financial position of the Company. Employee stock option and stock purchase plans The Company's employee stock option and stock purchase plans are accounted for under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees". Earnings per share Basic earnings per share is based upon the weighted-average number of common shares outstanding. Diluted earnings per share is based upon the weighted-average number of common shares and dilutive potential common shares outstanding. Potential common shares are outstanding options under the Company's employee stock option plans which are included under the treasury stock method. The following table sets forth the computation for basic and diluted earnings per share (in millions, except per share information): Three Months Ended Nine Months Ended September 30, September 30, 1999 1998 1999 1998 -------- -------- -------- -------- Numerator for basic and diluted earnings per share - net income $ 300.0 $ 221.0 $ 814.8 $ 624.6 ======== ======== ======== ======== Denominator: Denominator for basic earnings per share - weighted- average shares 1,021.5 1,020.4 1,022.1 1,020.6 Effect of dilutive securities - employee stock options 57.3 39.5 55.9 35.3 -------- -------- -------- -------- Denominator for diluted earnings per share - adjusted weighted-average shares 1,078.8 1,059.9 1,078.0 1,055.9 ======== ======== ======== ======== Basic earnings per share $ 0.29 $ 0.22 $ 0.80 $0.61 Diluted earnings per share $ 0.28 $ 0.21 $ 0.76 $0.59 9

Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from those estimates. Basis of presentation The financial information for the three and nine months ended September 30, 1999 and 1998 is unaudited but includes all adjustments (consisting only of normal recurring accruals, unless otherwise indicated) which the Company considers necessary for a fair presentation of the results of operations for these periods. Interim results are not necessarily indicative of results for the full fiscal year. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. 2. Debt As of September 30, 1999, the Company had $223 million of unsecured debt securities outstanding. These unsecured debt securities consisted of: 1) $100 million of debt securities that bear interest at a fixed rate of 6.5% and mature in 2007 that were issued in December 1997 under a $500 million debt shelf registration (the "Shelf"), 2) $100 million of debt securities that bear interest at a fixed rate of 8.1% and mature in 2097 and 3) $23 million of debt securities that bear interest at a fixed rate of 6.2% and mature in 2003. Under the Shelf, all of the remaining $400 million of debt securities available for issuance may be offered under the Company's medium-term note program from time to time with terms to be determined by market conditions. The Company has a commercial paper program which provides for unsecured short-term borrowings up to an aggregate face amount of $200 million. As of September 30, 1999, commercial paper with a face amount of $100 million was outstanding. These borrowings had maturities of less than two months and had effective interest rates averaging 5.4%. The Company also has an unsecured $150 million credit facility that expires on May 28, 2003. As of September 30, 1999, no amounts were outstanding under this line of credit. 10

3. Income taxes The provision for income taxes consists of the following (in millions): Three Months Ended Nine Months Ended September 30, September 30, 1999 1998 1999 1998 -------------- ------------- -------------- ------------- Federal (including U.S. possessions) $142.3 $ 94.6 $338.9 $256.1 State 10.5 6.5 27.2 18.0 -------------- ------------- -------------- ------------- $152.8 $101.1 $366.1 $274.1 ============== ============= ============== ============= The Company's effective tax rate for the three and nine months ended September 30, 1999 was 33.7% and 31%, respectively, compared with 31.4% and 30.5% for the same periods last year. The higher tax rates in the current year are primarily due to an increase in the current year's expected pretax income (i) combined with a provision in the federal tax law which caps tax benefits associated with the Company's Puerto Rico operations at the 1995 income level and (ii) without a corresponding increase in the amount of the Company's federal research and experimentation tax credit. During the third quarter of 1999, expected annual pretax income for 1999 increased primarily due to expected additional product sales in the fourth quarter of 1999 as a result of Year 2000 contingency planning (see "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Financial Outlook") and the benefit of the $49 million legal award recorded in the third quarter of 1999 (see Note 6, "Contingencies - Johnson & Johnson arbitrations"). 4. Stockholders' equity During the nine months ended September 30, 1999, the Company repurchased 19 million shares of its common stock at a total cost of $672.8 million under its common stock repurchase program. In October 1999, the Board of Directors authorized the repurchase of up to $2 billion of common stock through December 31, 2000, replacing the remaining $127.2 million of stock repurchases authorized in October 1998. Stock repurchased under the program is retired. On October 19, 1999, the Board of Directors approved a two-for-one split of the common stock to be effected in the form of a 100 percent stock dividend. The dividend will be distributed on November 19, 1999, to stockholders of record on November 5, 1999. Accordingly, the condensed consolidated financial statements and the accompanying notes have been retroactively adjusted to give recognition to this stock split. 5. Comprehensive income During the three and nine months ended September 30, 1999, total comprehensive income was $298.5 million and $793.9 million, respectively. During the three and nine months ended September 30, 11

1998, total comprehensive income was $231.3 million and $623.7 million, respectively. The Company's other comprehensive income/loss is comprised of unrealized gains and losses on the Company's available-for-sale securities and foreign currency translation adjustments. 6. Contingencies Johnson & Johnson arbitrations In September 1985, the Company granted Johnson & Johnson's affiliate, Ortho Pharmaceutical Corporation, a license relating to certain patented technology and know-how of the Company to sell a genetically engineered form of recombinant human erythropoietin, called Epoetin alfa, throughout the United States for all human uses except dialysis and diagnostics. A number of disputes have arisen between Amgen and Johnson & Johnson as to their respective rights and obligations under the various agreements between them, including the agreement granting the license (the "License Agreement"). A dispute between Amgen and Johnson & Johnson that has been the subject of an arbitration proceeding relates to the audit methodology currently employed by the Company to account for Epoetin alfa sales. The Company and Johnson & Johnson are required to compensate each other for Epoetin alfa sales that either party makes into the other party's exclusive market, sometimes described as "spillover" sales. The Company has established and is employing an audit methodology to measure each party's spillover sales and to allocate the net profits from those sales to the appropriate party. The arbitrator in this matter (the "Arbitrator") issued an opinion adopting the Company's audit methodology with certain adjustments and, subsequently, issued his final order confirming that the Company was the successful party in the arbitration. Pursuant to the final order in the arbitration, an independent panel was formed principally (i) to address ongoing challenges to the survey results for the years 1995 through 1999 and (ii) to refine the procedures for measuring the erythropoietin market as may be necessary. Pursuant to this procedure, Johnson & Johnson has brought challenges to certain survey results for certain periods. As a result of decisions made by this independent panel regarding certain of these challenges as well as other reduced uncertainties, the Company has reduced amounts previously provided for potential spillover liabilities by $49 million in the third quarter of 1999. Because the Company was the successful party in the arbitration, Johnson & Johnson was ordered to pay to the Company all costs and expenses, including reasonable attorneys' fees, that the Company incurred in the arbitration as well as one-half of the audit costs. The Company submitted a bill for such costs incurred over an eight year period in the amount of approximately $110 million. Johnson & Johnson has informed the Company that it intends to contest substantially all costs and expenses, including reasonable attorneys' fees, that the Company incurred in the arbitration as well as one-half of the audit costs. In addition, the Arbitrator has ruled that the Company cannot recover certain of its fees and costs. Although further clarification of the Arbitrator's order will be required, and 12

although he will determine at a later date the specific amount of the unrecoverable fees, the Company has estimated that the ruling reduces the Company's potential recovery of such fees and costs by approximately $12 million. In addition to determining that amount, the Arbitrator will determine how much of the Company's remaining claim the Company is entitled to recover from Johnson & Johnson. On October 26, 1998, Johnson & Johnson filed a petition in the Circuit Court of Cook County, Illinois seeking to vacate or modify the Arbitrator's award to the Company of all costs and expenses, including reasonable attorney's fees and costs, that the Company incurred in the arbitration. The Company has filed a motion to dismiss Johnson & Johnson's petition. That motion remains pending. Due to remaining uncertainties the Company has not recognized any benefit from the recovery of attorneys' fees and costs or audit costs. The Company has filed a demand in the arbitration to terminate Johnson & Johnson's rights under the License Agreement and to recover damages for breach of the License Agreement based on the Company's claim that Johnson & Johnson has intentionally sold PROCRIT(R) (the brand name under which Johnson & Johnson sells Epoetin alfa) into the Company's exclusive dialysis market. Johnson & Johnson disputed the Arbitrator's jurisdiction to decide the Company's demand. The Illinois Court of Appeals has denied Johnson & Johnson's appeal of the Company's successful motion for summary judgment affirming the Arbitrator has jurisdiction over this matter. Pursuant to the Arbitrator's ruling, discovery has commenced. Both Amgen and Johnson & Johnson have filed motions for summary judgment which are scheduled to be argued in December 1999. A trial date has been set for February 2001. The Company is unable to predict at this time the outcome of its demand for termination of the License Agreement or when it will be resolved. While it is not possible to predict accurately or determine the eventual outcome of the above described legal matters or various other legal proceedings (including patent disputes) involving Amgen, the Company believes that the outcome of these proceedings will not have a material adverse effect on its annual financial statements. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Liquidity and Capital Resources The Company had cash, cash equivalents and marketable securities of $1,524 million at September 30, 1999, compared with $1,276 million at December 31, 1998. Cash provided by operating activities has been and is expected to continue to be the Company's primary source of funds. During the nine months ended September 30, 1999, operations provided $884 million of cash compared with $752.8 million during the same period last year. Capital expenditures totaled $211.3 million for the nine months ended September 30, 1999, compared with $320 million for the same 13

period a year ago. The Company anticipates spending approximately $300 million to $350 million in 1999 on capital projects and equipment to expand the Company's global operations. The Company receives cash from the exercise of employee stock options. During the nine months ended September 30, 1999, stock options and their related tax benefits provided $312.1 million of cash compared with $275.8 million for the same period last year. Proceeds from the exercise of stock options and their related tax benefits will vary from period to period based upon, among other factors, fluctuations in the market value of the Company's stock relative to the exercise price of such options. The Company has a stock repurchase program primarily to offset the dilutive effect of its employee stock option and stock purchase plans. During the nine months ended September 30, 1999, the Company purchased 19 million shares of its common stock at a cost of $672.8 million compared with 46.3 million shares purchased at a cost of $692.8 million during the same period last year. In October 1999, the Board of Directors authorized the repurchase of up to $2 billion of common stock through December 31, 2000, replacing the remaining $127.2 million of stock repurchases authorized in October 1998. To provide for financial flexibility and increased liquidity, the Company has established several sources of debt financing. As of September 30, 1999, the Company had $223 million of unsecured debt securities outstanding. These unsecured debt securities consisted of: 1) $100 million of debt securities that bear interest at a fixed rate of 6.5% and mature in 2007 that were issued in December 1997 under a $500 million debt shelf registration (the "Shelf"), 2) $100 million of debt securities that bear interest at a fixed rate of 8.1% and mature in 2097 and 3) $23 million of debt securities that bear interest at a fixed rate of 6.2% and mature in 2003. Under the Shelf, all of the remaining $400 million of debt securities available for issuance may be offered under the Company's medium-term note program. The Company's sources of debt financing also include a commercial paper program which provides for short-term borrowings up to an aggregate face amount of $200 million. As of September 30, 1999, commercial paper with a face amount of $100 million was outstanding. These borrowings had maturities of less than two months and had effective interest rates averaging 5.4%. In addition, the Company has an unsecured $150 million credit facility that expires on May 28, 2003. This credit facility supports the Company's commercial paper program. As of September 30, 1999, no amounts were outstanding under this line of credit. The primary objectives for the Company's investment portfolio are liquidity and safety of principal. Investments are made to achieve the highest rate of return to the Company, consistent with these two objectives. The Company's investment policy limits investments to certain types of instruments issued by institutions with investment grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company 14

invests its excess cash in securities with varying maturities to meet projected cash needs. The Company believes that existing funds, cash generated from operations and existing sources of debt financing are adequate to satisfy its working capital and capital expenditure requirements for the foreseeable future, as well as to support its stock repurchase program. However, the Company may raise additional capital from time to time. Results of Operations Product sales Product sales were $769.2 million and $2,195.4 million during the three and nine months ended September 30, 1999, respectively. These amounts represent increases of $127.4 million and $375.6 million, or 20% and 21%, respectively, over the same periods last year. Quarterly product sales volume is influenced by a number of factors, including underlying demand and wholesaler inventory management practices. Due to Year 2000 contingency planning, the Company expects certain wholesalers to significantly build up their inventories of EPOGEN(R) and NEUPOGEN(R) in the fourth quarter of 1999 and then draw down such inventories in the first quarter of 2000 (see "- Financial Outlook"). EPOGEN(R) (Epoetin alfa) EPOGEN(R) sales were $448.7 million and $1,271.6 million for the three and nine months ended September 30, 1999, respectively. These amounts represent increases of $99 million and $281 million or 28% over each of the same periods last year. These increases were primarily due to the administration of higher doses and the continuing growth in the U.S. dialysis patient population. The administration of higher doses of EPOGEN(R) was principally due to changes in reimbursement announced in March and June 1998 by the Health Care Financing Administration ("HCFA"), discussed below, as well as many dialysis providers using better anemia management practices, including using hemoglobin instead of hematocrit to measure red blood cell volume. In September 1997, HCFA implemented changes (the "HCFA Policy Changes") to its reimbursement policy for EPOGEN(R) that had been set out in a May 1997 program memorandum. Prior to the HCFA Policy Changes, fiscal intermediaries under contract with HCFA were authorized to pay reimbursement claims for patients whose hematocrits exceeded 36 percent, the top of the suggested target hematocrit range in the product's labeling, if deemed medically justified. Under the HCFA Policy Changes, medical justification was not accepted for payment of claims of hematocrits that exceeded 36 percent and, if the current month's hematocrit was greater than 36 percent and the patient's hematocrit exceeded 36.5 percent on an historical 90-day "rolling average" basis, reimbursement for the current month would be denied in full. Beginning in the second quarter of 1997, the Company experienced a decline in the growth 15

rate of EPOGEN(R) sales as dialysis providers attempted to lower hematocrits by lowering or withholding EPOGEN(R) doses in order to avoid or minimize claim denials under the HCFA Policy Changes. In March 1998, HCFA announced the easing of restrictions on reimbursement that had been instituted under the HCFA Policy Changes. In June 1998, HCFA announced that it was replacing the previous policies (September and March) with new guidelines. In March 1998, HCFA issued a program memorandum with two revisions (the "March HCFA Revisions") to the HCFA Policy Changes. The first revision provided that, for a month in which the three month "rolling average" hematocrit exceeds 36.5 percent, HCFA would pay the lower of 100 percent of the actual dosage billed for that month, or 80 percent of the prior month's allowable EPOGEN(R) dosage. The second revision re-established authorization to make payment for EPOGEN(R) when a patient's hematocrit exceeded 36 percent when accompanied by documentation establishing medical necessity. Following its announcement in June 1998, HCFA issued a program memorandum in July 1998 (the "July Program Memorandum"), with new reimbursement guidelines, which replaced the previous program memoranda cited above. (As noted in the July Program Memorandum, it may be discarded after one year.) The July Program Memorandum stated that pre-payment review of claims would be eliminated and fiscal intermediaries should conduct post-payment reviews of those dialysis providers with an atypical number of patients with hematocrit levels above a 90- day "rolling average" of 37.5 percent. Additionally, HCFA stated that it would encourage dialysis providers to maintain a hematocrit level within the range of 33 to 36 percent as recommended by the Dialysis Outcomes Quality Initiative. HCFA also stated in its July Program Memorandum that it planned to develop a national policy for medical justification for patients whose hematocrits should be maintained over 36 percent. In the interim, physicians were to document and provide medical justification for patients whose hematocrits need to be maintained over 36 percent. NEUPOGEN(R) (Filgrastim) Worldwide NEUPOGEN(R) sales were $313.3 million and $903.8 million for the three and nine months ended September 30, 1999. These amounts represent increases of $26 million and $84.7 million or 9% and 10%, respectively, over the same periods last year. These increases were primarily due to the growth in demand worldwide within the cancer chemotherapy markets and the effect of higher prices in the U.S. Cost containment pressures in the U.S. health care marketplace have limited growth in domestic NEUPOGEN(R) sales. These pressures are expected to continue to influence growth for the foreseeable future. In addition, the Company faces competition from other granulocyte colony stimulating factor ("CSF") products in the U.S. and the European Union ("EU") markets. Amgen's CSF market share in the EU has remained relatively constant over the last few years, however, the competitive intensity has increased and is expected to continue to increase. 16

Other product sales INFERGEN(R) (Interferon alfacon-1) sales were $6.8 million and $19.4 million for the three and nine months ended September 30, 1999. These amounts represent increases of $2 million and $9.3 million or 42% and 92%, respectively, over the same periods last year. INFERGEN(R) was launched in October 1997 for the treatment of chronic hepatitis C virus infection. There are existing treatments, including a new therapy launched in 1998, for this infection against which INFERGEN(R) competes. The Company cannot predict the extent to which it will penetrate this market. Cost of sales Cost of sales as a percentage of product sales was 12.9% and 13.2% for the three and nine months ended September 30, 1999, respectively, compared with 13.6% and 13.7% for the same periods last year. Research and development During the three and nine months ended September 30, 1999, research and development expenses increased $32.4 million and $109.6 million, or 20% and 23%, respectively, compared with the same periods last year. These increases were primarily due to higher staff-related costs necessary to support ongoing product development activities and costs related to the collaboration with PRAECIS PHARMACEUTICALS INCORPORATED. Selling, general and administrative Selling, general and administrative expenses increased $25.7 million and $80.7 million, or 19% and 22%, during the three and nine months ended September 30, 1999 compared with the same periods last year. These increases were primarily due to higher staff-related costs, outside marketing expenses, information management consulting fees and allowances for doubtful accounts. Legal award Included in the third quarter of 1999 was a credit of $49 million which reflected reduced uncertainty for the Company's potential spillover liabilities to Johnson & Johnson. See Note 6 to the Condensed Consolidated Financial Statements, "Contingencies - Johnson & Johnson arbitrations". Income taxes The Company's effective tax rate for the three and nine months ended September 30, 1999 was 33.7% and 31%, respectively, compared with 31.4% and 30.5% for the same periods last year. The higher tax rates in the current year are primarily due to an increase in the current year's expected pretax income (i) combined with a provision in the federal tax law which caps tax benefits associated with the Company's Puerto Rico operations at the 1995 income level and (ii) without a corresponding increase in the amount of the Company's federal research and 17

experimentation tax credit. During the third quarter of 1999, expected annual pretax income for 1999 increased primarily due to expected additional product sales in the fourth quarter of 1999 as a result of Year 2000 contingency planning (see "-Financial Outlook") and the benefit of the $49 million legal award recorded in the third quarter of 1999 (see "- Legal award"). Foreign currency transactions The Company has a program to manage certain portions of its exposure to fluctuations in foreign currency exchange rates arising from international operations. The Company generally hedges the receivables and payables with foreign currency forward contracts, which typically mature within one to three months. The Company uses foreign currency option and forward contracts which generally expire within 12 months to hedge certain anticipated future sales and expenses. At September 30, 1999, outstanding foreign currency option and forward contracts totaled $73.5 million and $48.4 million, respectively. Year 2000 The Year 2000 problem (the "Year 2000 Problem") results from computer programs and devices that do not differentiate between the year 1900 and the year 2000 because they were written using two digits rather than four to define the applicable year; accordingly, computer systems that have time-sensitive calculations may not properly recognize the year 2000. This could result in system failures or miscalculations causing disruptions of the Company's operations, including, without limitation, manufacturing, distribution, clinical development, research and other business activities. The Year 2000 Problem is likely to affect the Company's computer hardware, software, systems, devices, applications and manufacturing equipment, including without limitation, its non- information technology systems (such as elevators, HVAC equipment, security systems and other equipment containing embedded technology such as microcontrollers) (collectively, "Computer Systems"). Amgen believes that it is substantially year 2000 ready. Like many corporations, the Company does not have any previous experience with an issue like the Year 2000 Problem. The Year 2000 Problem potentially affects the Company across its worldwide locations and within substantially all of its business activities. Although the Company believes it has developed an appropriate program to address the Year 2000 Problem, it cannot guarantee that its program will succeed. The following is a discussion of the Company's year 2000 program. Amgen appointed a program manager for year 2000 compliance. Amgen reviewed its Computer Systems to identify those areas that could be affected by the Year 2000 Problem and has substantially completed a program to address year 2000 issues in its functional areas and site locations worldwide. The Company has identified the following three principal areas of potential Computer Systems exposure at Amgen to the Year 2000 Problem, in addition to supplier and customer issues which are discussed elsewhere: 18

- Process Control, Instruments and Environmental Monitoring and Control Systems: these types of systems are used in the Company's manufacturing and clinical trial processes, among other operations. These generally are systems, devices and instruments which utilize date functionality and generate, send, receive or manipulate date-stamped data and signals. These systems may be found in data acquisition/processing software, laboratory instrumentation and other equipment with embedded code, for example. These devices and instruments may be controlled by installed software, firmware or other embedded control algorithms. - Servers, Desktops and Infrastructure: these generally are desktop computers (PCs and Macintosh) and server computer equipment (NT and UNIX), telecommunications, local area networks, wide area networks, and include system hardware, firmware, installed commercial application software, e- mail, video teleconferencing and electronic calendaring systems, for example. - Custom Applications and Business Systems: these generally are systems which the Company either wrote or for which the Company has purchased the source code, or applications purchased from an external vendor. These systems include applications developed or purchased by a functional area on computer systems located within Amgen's corporate departments and operated by departmental personnel, such as Amgen's core business systems (including financial systems and sales operations systems), fund transfer systems and personnel management systems. For each of these areas, Amgen planned and substantially completed an inventory, business risk assessment, remediation, testing and implementation phase. While the Company believes that it has implemented business critical Computer Systems in their year 2000-compliant form, if modifications of such business critical Computer Systems are not successful, the Year 2000 Problem could have a material adverse effect on the operations and financial position of the Company. Additionally, while the Company has already met substantially all of its internal deadlines, the Company cannot guarantee that it will meet further internal or external deadlines for year 2000 compliance. The Company is using both internal and external resources to identify, correct/reprogram and test its Computer Systems for year 2000 compliance. However, the Company cannot guarantee that these resources will continue to be available at a reasonable cost or at all, due, in part, to competing demands for these resources which could occur on or after January 1, 2000. The Company has identified critical providers of information, goods and services ("Suppliers") in order to assess their year 2000 compliance/readiness. Suppliers have been prioritized based on business criticality and year 2000 surveys were distributed. The Company has substantially completed the assessment of year 2000 readiness of its critical Suppliers. As part of its assessment process, the Company has visited and will continue to visit selected critical Suppliers to confirm their year 2000 readiness. The Company does not intend to contact entities that are not critical and cannot 19

guarantee that such entities will be year 2000 compliant. The failure of Suppliers to become year 2000 compliant on a timely basis, or at all, could have a material adverse effect on the Company. The Company has identified its key customers and is working to understand year 2000 exposure and compliance in that area. However, the Company believes that the failure of its key customers to become year 2000 compliant on a timely basis, or at all, could have a material adverse effect on the Company. The Company may also be affected by the failure of other third parties to be year 2000 compliant even though these third parties do not directly conduct business with Amgen. For example, the failure of state, federal and private payors or reimbursers to be year 2000 compliant and thus unable to make timely, proper or complete payments to sellers and users of the Company's products, could have a material adverse effect on the Company. The Health Care Financing Administration ("HCFA"), the principal federal reimburser for the Company's marketed products, reports that it has fixed its internal systems; HCFA also has stated that it is carrying out year 2000 outreach programs to Medicare providers. Nevertheless, HCFA reports that reviews of contingency plans for Medicare managed care organizations indicate that fifty percent of contingency plans for national chains need "major improvements". Additionally, according to published reports, only a minority of the healthcare providers that submit electronic claims to Medicare have tested their computer systems with Medicare contractors. In developing a contingency plan for the Year 2000 Problem, the Company believes that its "most reasonably likely worst case year 2000 scenario" (the "Scenario") includes periodic, sporadic disruptions to the delivery of power, water and normal telecommunication services to the Company's worldwide locations and impaired transportation, including limited air traffic capacity, which may occur in the first few months of 2000 (collectively, "Service Disruptions"). The Scenario also contemplates the failure of Computer Systems of third parties that use the Company's products and seek reimbursement for the cost of these products (such as hospitals, physicians and dialysis providers) and of third parties who reimburse for such costs (such as HCFA). Under the Scenario, the Company's manufacturing, distribution, and research and clinical development activities, among others, could be adversely affected. Although the Company believes it has identified the major elements of its "most reasonably likely worst case year 2000 scenario", there can be no assurance that the Company has accurately or adequately anticipated the effects of the Year 2000 Problem on the Company or third parties, or that the Company will develop an adequate contingency plan based on the Scenario or otherwise. As part of its regular business operations, the Company maintains a business continuity plan. In anticipation of the Year 2000 Problem, the Company evaluated its existing business continuity plan in light of the Scenario and modified this plan, as necessary, in order to develop its year 2000 contingency plan (the "Plan"). Generally, the Plan is designed to protect the Company's assets, and address the Company's critical business operations, including (i) 20

manufacturing, order processing and delivery of the Company's products to its customers and product candidates to clinical trial locations and (ii) paying for goods and services. The principal elements of the Plan are as follows: Build Inventories: Where appropriate, the Plan provides that the Company will maintain extra supplies of resources deemed to be the most critical or, in the Company's opinion, which would be hard to replace under the Scenario. For example, the Company plans to maintain extra quantities of single-source raw materials inventory used to manufacture products. The Company also plans to increase its product and product candidate inventories. The estimated additional cost of building raw material, product and product candidate inventories is not expected to be material. The Company also maintains a substantial portion of its inventory at its central distribution sites that will facilitate distribution throughout the continental U.S. and the European Union in the event of a Year 2000 Problem. In some cases, the Company plans to qualify additional suppliers of goods (such as raw materials) and services, although the Company cannot guarantee the year 2000 compliance of alternate suppliers. Develop Alternatives: In some cases Amgen has established alternatives to its customary manner of doing business. For example, the Company has alternative sources of power and telecommunications services, and alternate shippers for its products. In addition, as part of the Plan, the Company intends to permit its major U.S. wholesalers to purchase limited additional quantities of inventory so as to minimize possible disruptions to the supply of the Company's products to patients. See "- Financial Outlook". In Europe, wholesaler approaches vary by country. Manual Workarounds: Certain of Amgen's business activities, such as order processing and payments, are computerized. Under the Scenario, these operations could be affected. Many of Amgen's business activities are power dependent and may be affected by Service Disruptions. The Plan provides that some computerized functions will be handled manually if the Company's Computer Systems are unable to function either because of the Year 2000 Problem, Service Disruptions or otherwise. For example, the Company is capable of issuing manual disbursements to pay for goods and services. Also, based on historical ordering patterns, the Company may execute pre-arranged standing order shipments to U.S. wholesalers who so desire them. Reschedule Business Activities: The Company has adjusted the timing of certain business activities so that they do not coincide with the first several weeks of 2000, which is a time period included in the Scenario. For example, the Company plans to shift its semi-annual manufacturing maintenance period at most of its U.S. manufacturing facilities from the last two weeks of 1999 to the first two weeks of 2000. Suspend Activities: In addition to the elements of the Plan described above, the Company also plans that in the event of Service Disruptions or failures of the Company's Computer Systems, the 21

Company would suspend certain business activities. For example, if the Company is unable to process its billing services as usual, then billing functions would be suspended until computerized operations could resume. Also, if, as contemplated by the Scenario, there is no water, the life-safety measures of the Plan require that only those employees essential to business continuity and key management would be permitted on site. The examples provided above are designed to illustrate the operation of certain elements of the Plan and are not intended to be exhaustive or exclusive descriptions of the Plan. To help address unanticipated problems, the Plan provides that select employees and contractors will be on-site during the transition into the year 2000 at the Company's major facilities worldwide. Although the Company reasonably believes that it has identified strategies and made available resources in developing the Plan to protect and restore its most critical processes in response to the Scenario, there can be no assurance the Plan will accurately or adequately address all the risks that may arise as a result of the Scenario, the Year 2000 Problem or otherwise. The Company anticipates implementing the Plan by the end of November 1999. As of September 30, 1999, total expenditures related to the Company's year 2000 program, including, without limitation, anticipated upgrades, remediation and new Computer Systems, are expected to range from $45 million to $50 million, approximately one-third of which is expected to be capital expenditures. However, these amounts are only estimates and are based on information currently available to the Company; the Company cannot guarantee that these amounts will be adequate to address the Company's year 2000 compliance needs. As of September 30, 1999, the Company estimates that it had incurred approximately $36 million in its year 2000 efforts, including without limitation, internal staff costs, outside consulting fees and Computer Systems upgrades. The statements set forth herein concerning the Year 2000 Problem which are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. There can be no guarantee that any estimates or other forward-looking statements will be achieved and actual results could differ significantly from those planned or contemplated. The Company plans to update the status of its year 2000 program as necessary in its periodic filings and in accordance with applicable securities laws. Financial Outlook The Company expects the sales growth rate for EPOGEN(R) in 1999 to be in the mid-twenties. In 2000, the Company expects EPOGEN(R) sales growth to be in the mid-teens. These expected growth rates exclude the impact of wholesaler inventory purchases related to Year 2000 contingency planning discussed below. The Company believes that dialysis providers have increased doses primarily in response to the July Program Memorandum and due to many dialysis providers 22

using hemoglobin instead of hematocrit to measure red blood cell volume (see "Results of Operations - Product sales - EPOGEN(R) (Epoetin alfa)"). The Company also believes that increases in the U.S. dialysis patient population and dose will continue to grow EPOGEN(R) sales in the near term, although the Company anticipates that as the average hematocrit rises, dose will grow at a slower rate. Patients receiving treatment for end stage renal disease are covered primarily under medical programs provided by the federal government. Therefore, EPOGEN(R) sales may also be affected by future changes in reimbursement rates or a change in the basis for reimbursement by the federal government. In their fiscal year 2000 budget, the Clinton administration has proposed a Medicare cost savings plan which includes a provision for cutting Medicare reimbursement of EPOGEN(R) by 10%. This proposal will be addressed during the federal government's fiscal year 2000 budget process. The Company believes the proposal, if enacted, would primarily affect dialysis providers that use EPOGEN(R) and it is difficult to predict its impact on Amgen. The Company expects a high single- to low double-digit sales growth rate for NEUPOGEN(R) in 1999. In 2000, the NEUPOGEN(R) sales growth rate is expected to be in the high single digits. These expected growth rates exclude the impact of wholesaler inventory purchases related to Year 2000 contingency planning discussed below. Future NEUPOGEN(R) sales growth is dependent primarily upon further penetration of existing markets, the effects of competitive products and the timing and nature of additional indications for which the product may be approved. NEUPOGEN(R) usage is expected to continue to be affected by cost containment pressures on health care providers worldwide. In addition, reported NEUPOGEN(R) sales will continue to be affected by changes in foreign currency exchange rates, government budgets and increased competition in Europe. In both domestic and foreign markets, sales of NEUPOGEN(R) are dependent, in part, on the availability of reimbursement from third party payors such as governments (for example, Medicare and Medicaid programs in the U.S.) and private insurance plans. Therefore, NEUPOGEN(R) sales may also be affected by future changes in reimbursement rates or changes in the bases for reimbursement. In their fiscal year 2000 budget, the Clinton administration has proposed a reduction in the basis upon which Medicare reimburses outpatient prescription drugs from the current 95% of average wholesale price ("AWP") to a proposed 83% of AWP. This proposal would impact reimbursement of NEUPOGEN(R). The Company believes that this new recommendation, if enacted, would primarily affect customers that use NEUPOGEN(R) and it is difficult to predict its impact on Amgen. Due to Year 2000 contingency planning, the Company expects certain wholesalers to significantly build up their inventories of EPOGEN(R) and NEUPOGEN(R) in the fourth quarter of 1999 and then draw down such inventories in the first quarter of 2000. Excluding the impact of these expected changes in wholesaler purchases, the Company anticipates the growth rate for total product sales to be close to 20 23

percent in 1999 and in the low double-digit range in 2000. Assuming that the federal government will extend the research and experimentation tax credit for the second half of 1999 and for all of 2000, the Company expects earnings per share will be in the range of $0.95 to $0.97 (adjusted for the two-for-one stock split) for 1999 and earnings per share growth to be in the low double digits for 2000. These expectations for earnings per share exclude the impact of wholesaler purchases related to Year 2000 contingency planning and the impact of the $49 million legal award recorded in the third quarter of 1999. Estimates of future product sales, operating expenses and earnings per share are necessarily speculative in nature and are difficult to predict with accuracy. Except for the historical information contained herein, the matters discussed herein are by their nature forward-looking. Investors are cautioned that forward-looking statements or projections made by the Company, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Reference is made in particular to forward-looking statements regarding product sales, earnings per share and expenses. Amgen operates in a rapidly changing environment that involves a number of risks, some of which are beyond the Company's control. Future operating results and the Company's stock price may be affected by a number of factors, including, without limitation: (i) the results of preclinical and clinical trials; (ii) regulatory approvals of product candidates, new indications and manufacturing facilities; (iii) reimbursement for Amgen's products by governments and private payors; (iv) health care guidelines and policies relating to Amgen's products; (v) intellectual property matters (patents) and the results of litigation; (vi) competition; (vii) fluctuations in operating results and (viii) rapid growth of the Company. These factors and others are discussed herein and in the sections appearing in "Item 1. Business - Factors That May Affect Amgen" in the Company's Annual Report on Form 10-K for the year ended December 31, 1998 which sections are incorporated herein by reference and filed as an exhibit hereto. Legal Matters The Company is engaged in arbitration proceedings with one of its licensees. For a discussion of these matters, see Note 6 to the Condensed Consolidated Financial Statements. 24

PART II - OTHER INFORMATION Item 1. LEGAL PROCEEDINGS Legal proceedings are reported in the Company's Annual Report on Form 10-K for the year ended December 31, 1998, with material developments since that report described in the Company's Form 10-Q for the quarters ended March 31, 1999, June 30, 1999 and below. While it is not possible to predict accurately or to determine the eventual outcome of these matters, the Company believes that the outcome of these proceedings will not have a material adverse effect on the annual financial statements of the Company. Hoechst Marion Roussel and Transkaryotic Therapies litigation On October 7, 1999, Amgen filed an amended complaint that Transkaryotic Therapies, Inc. ("TKT") and Hoechst Marion Roussel Inc. ("HMR") have infringed or will infringe the three Amgen patents originally in suit and two patents newly added to the litigation. TKT and HMR filed their answer to the amended complaint on October 22, 1999, and asserted that the five patents-in-suit are not infringed or are invalid and/or unenforceable. The court has set a trial date of April 2000. INFERGEN(R) litigation In February 1999, the U.S. District Court for the District of Delaware granted Schering-Plough Corporation's ("Schering") motion to dismiss Amgen's counterclaims as moot and entered judgment of noninfringement in favor of Amgen. Schering and Biogen, Inc. are seeking review of this decision on appeal. FoxMeyer Health Corporation The Federal Bankruptcy Court in Delaware has denied on the grounds of vagueness the Company's and McKesson Corporation's and the eleven other manufacturer defendants' renewed motion for summary judgement. On September 3, 1999, all stays regarding discovery expired and the parties have begun serving and answering written discovery. Avatex Corporation (formerly FoxMeyer Corporation)("Avatex") has responded to Amgen's written discovery requests and as a result of Avatex's responses, Amgen has filed a motion for discovery sanctions and a motion for protective order against Avatex. Amgen has also filed a motion asserting certain pleading defects in Avatex's petition. No hearing has been scheduled for Amgen's motions. The District Court of Dallas County, Dallas, Texas has set a trial date of September 2000. 25

Johnson & Johnson arbitrations The Company is engaged in arbitration proceedings with one of its licensees. See Note 6 to the Condensed Consolidated Financial Statements, "Contingencies - Johnson & Johnson arbitrations". Item 6. Exhibits and Reports on Form 8-K (a) Reference is made to the Index to Exhibits included herein. (b) Reports on Form 8-K - none 26

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Amgen Inc. (Registrant) Date: 11/10/99 By:/s/Kathryn E. Falberg - ---------------- ------------------------------- Kathryn E. Falberg Senior Vice President, Finance and Chief Financial Officer Date: 11/10/99 By:/s/Marc M.P. de Garidel - ---------------- ------------------------------- Marc M.P. de Garidel Vice President, Controller and Chief Accounting Officer 27

AMGEN INC. INDEX TO EXHIBITS Exhibit No. Description 3.1 Restated Certificate of Incorporation as amended. (17) 3.2 Amended and Restated Bylaws. (26) 3.3 Certificate of Amendment of Restated Certificate of Incorporation. (26) 3.4 Certificate of Amendment of Certificate of Designations of Series A Junior Participating Preferred Stock. (26) 4.1 Indenture dated January 1, 1992 between the Company and Citibank N.A., as trustee. (8) 4.2 First Supplement to Indenture, dated February 26, 1997 between the Company and Citibank N.A., as trustee. (14) 4.3 Officer's Certificate pursuant to Sections 2.1 and 2.3 of the Indenture, as supplemented, establishing a series of securities "8- 1/8% Debentures due April 1, 2097." (16) 4.4 8-1/8% Debentures due April 1, 2097. (16) 4.5 Form of stock certificate for the common stock, par value $.0001 of the Company. (17) 4.6 Officer's Certificate pursuant to Sections 2.1 and 2.3 of the Indenture, dated as of January 1, 1992, as supplemented by the First supplemental Indenture, dated as of February 26, 1997, each between the Company and Citibank, N.A., as Trustee, establishing a series of securities entitled "6.50% Notes Due December 1, 2007". (20) 4.7 6.50% Notes Due December 1, 2007 described in Exhibit 4.6. (20) 4.8 Corporate Commercial Paper - Master Note between and among Amgen Inc., as Issuer, Cede & Co., as nominee of The Depository Trust Company and Citibank, N.A. as Paying Agent. (23) 10.1 Company's Amended and Restated 1991 Equity Incentive Plan. (26) 10.2 Sixth Amendment to the Company's Amended and Restated Retirement and Savings Plan as amended and restated April 1, 1996. (25) 10.3 Shareholder's Agreement of Kirin-Amgen, Inc., dated May 11, 1984, between the Company and Kirin Brewery Company, Limited (with certain confidential information deleted therefrom). (1) 10.4 Amendment Nos. 1, 2, and 3, dated March 19, 1985, July 29, 1985 and December 19, 1985, respectively, to the Shareholder's Agreement of Kirin-Amgen, Inc., dated May 11, 1984 (with certain confidential information deleted therefrom). (3) 10.5 Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated, September 30, 1985 between the Company and Ortho Pharmaceutical Corporation 28

(with certain confidential information deleted therefrom). (2) 10.6 Product License Agreement, dated September 30, 1985, and Technology License Agreement, dated September 30, 1985 between Kirin-Amgen, Inc. and Ortho Pharmaceutical Corporation (with certain confidential information deleted therefrom). (3) 10.7 Company's Amended and Restated Employee Stock Purchase Plan. (12) 10.8 Research, Development Technology Disclosure and License Agreement PPO, dated January 20, 1986, by and between the Company and Kirin Brewery Co., Ltd. (4) 10.9 Amendment Nos. 4 and 5, dated October 16, 1986 (effective July 1, 1986) and December 6, 1986 (effective July 1, 1986), respectively, to the Shareholders Agreement of Kirin-Amgen, Inc. dated May 11, 1984 (with certain confidential information deleted therefrom). (5) 10.10 Assignment and License Agreement, dated October 16, 1986, between the Company and Kirin-Amgen, Inc. (with certain confidential information deleted therefrom). (5) 10.11 G-CSF European License Agreement, dated December 30, 1986, between Kirin-Amgen, Inc. and the Company (with certain confidential information deleted therefrom). (5) 10.12 Research and Development Technology Disclosure and License Agreement: GM-CSF, dated March 31, 1987, between Kirin Brewery Company, Limited and the Company (with certain confidential information deleted therefrom). (5) 10.13 Company's Amended and Restated 1988 Stock Option Plan. (12) 10.14 Company's Amended and Restated Retirement and Savings Plan. (12) 10.15 Amendment, dated June 30, 1988, to Research, Development, Technology Disclosure and License Agreement: GM-CSF dated March 31, 1987, between Kirin Brewery Company, Limited and the Company. (6) 10.16 Agreement on G-CSF in Certain European Countries, dated January 1, 1989, between Amgen Inc. and F. Hoffmann-La Roche & Co. Limited Company (with certain confidential information deleted therefrom). (7) 10.17 Partnership Purchase Agreement, dated March 12, 1993, between the Company, Amgen Clinical Partners, L.P., Amgen Development Corporation, the Class A limited partners and the Class B limited partner. (9) 10.18 Amgen Inc. Supplemental Retirement Plan (As Amended and Restated Effective January 1, 1998). (23) 10.19 Promissory Note of Mr. Kevin W. Sharer, dated June 4, 1993. (10) 10.20 Amended and Restated Amgen Performance Based Management Incentive Plan. (26) 10.21 Credit Agreement, dated as of May 28, 1998, among Amgen Inc., the Borrowing Subsidiaries named therein, the Banks named therein, Citibank, N.A., as Issuing Bank, and Citicorp USA, Inc., as Administrative Agent. (24) 10.22 Promissory Note of Mr. George A. Vandeman, dated December 15, 1995. (11) 29

10.23 Promissory Note of Mr. George A. Vandeman, dated December 15, 1995. (11) 10.24 Promissory Note of Mr. Stan Benson, dated March 19, 1996. (11) 10.25 Amendment No. 1 to the Company's Amended and Restated Retirement and Savings Plan. (12) 10.26 Seventh Amendment to the Amgen Retirement and Savings Plan as Amended and Restated effective April 1, 1996. (26) 10.27 Amendment Number 2 to the Company's Amended and Restated Retirement and Savings Plan dated April 1, 1996. (15) 10.28 Amgen Inc. Change of Control Severance Plan effective as of October 20, 1998. (25) 10.29 Preferred Share Rights Agreement, dated February 18, 1997, between Amgen Inc. and American Stock Transfer and Trust Company, Rights Agent. (13) 10.30 First Amendment, effective January 1, 1998, to the Company's Amended and Restated Employee Stock Purchase Plan. (18) 10.31 Third Amendment, effective January 1, 1997, to the Company's Amended and Restated Retirement and Savings Plan dated April 1, 1996. (18) 10.32 Binding Term Sheet, dated August 20, 1997, between Guilford Pharmaceuticals Inc. and GPI NIL Holdings, Inc., and Amgen Inc. (with certain confidential information deleted therefrom). (19) 10.33 Promissory Note of Ms. Kathryn E. Falberg, dated April 7, 1995. (21) 10.34 Promissory Note of Mr. Edward F. Garnett, dated July 18, 1997. (21) 10.35 Fourth Amendment to the Company's Amended and Restated Retirement and Savings Plan as amended and restated effective April 1, 1996. (21) 10.36 Fifth Amendment to the Company's Amended and Restated Retirement and Savings Plan as amended and restated effective April 1, 1996. (21) 10.37 Company's Amended and Restated 1987 Directors' Stock Option Plan. (15) 10.38 Amended and Restated Agreement on G-CSF in the EU between Amgen Inc. and F. Hoffmann-La Roche Ltd (with certain confidential information deleted therefrom). (23) 10.39 Collaboration and License Agreement, dated December 15, 1997, between the Company, GPI NIL Holdings, Inc. and Guilford Pharmaceuticals Inc. (with certain confidential information deleted therefrom). (22) 27* Financial Data Schedule. 99* Sections appearing under the heading "Business - Factors That May Affect Amgen" in the Company's Annual Report on Form 10-K for the year ended December 31, 1998. - ---------------- * Filed herewith. (1) Filed as an exhibit to the Annual Report on Form 10-K for the year ended March 31, 1984 on June 26, 1984 and incorporated herein by reference. 30

(2) Filed as an exhibit to Quarterly Report on Form 10-Q for the quarter ended September 30, 1985 on November 14, 1985 and incorporated herein by reference. (3) Filed as an exhibit to Quarterly Report on Form 10-Q for the quarter ended December 31, 1985 on February 3, 1986 and incorporated herein by reference. (4) Filed as an exhibit to Amendment No. 1 to Form S-1 Registration Statement (Registration No. 33-3069) on March 11, 1986 and incorporated herein by reference. (5) Filed as an exhibit to the Form 10-K Annual Report for the year ended March 31, 1987 on May 18, 1987 and incorporated herein by reference. (6) Filed as an exhibit to Form 8 amending the Quarterly Report on Form 10-Q for the quarter ended June 30, 1988 on August 25, 1988 and incorporated herein by reference. (7) Filed as an exhibit to the Form 8 dated November 8, 1989, amending the Annual Report on Form 10-K for the year ended March 31, 1989 on June 28, 1989 and incorporated herein by reference. (8) Filed as an exhibit to Form S-3 Registration Statement dated December 19, 1991 and incorporated herein by reference. (9) Filed as an exhibit to the Form 8-A dated March 31, 1993 and incorporated herein by reference. (10) Filed as an exhibit to the Form 10-Q for the quarter ended September 30, 1993 on November 12, 1993 and incorporated herein by reference. (11) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1995 on March 29, 1996 and incorporated herein by reference. (12) Filed as an exhibit to the Form 10-Q for the quarter ended September 30, 1996 on November 5, 1996 and incorporated herein by reference. (13) Filed as an exhibit to the Form 8-K Current Report dated February 18, 1997 on February 28, 1997 and incorporated herein by reference. (14) Filed as an exhibit to the Form 8-K Current Report dated March 14, 1997 on March 14, 1997 and incorporated herein by reference. (15) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1996 on March 24, 1997 and incorporated herein by reference. (16) Filed as an exhibit to the Form 8-K Current Report dated April 8, 1997 on April 8, 1997 and incorporated herein by reference. (17) Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1997 on May 13, 1997 and incorporated herein by reference. (18) Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1997 on August 12, 1997 and incorporated herein by reference. (19) Filed as exhibit 10.47 to the Guilford Pharmaceuticals Inc. Form 8-K Current Report dated August 20, 1997 on September 4, 1997 and incorporated herein by reference. (20) Filed as an exhibit to the Form 8-K Current Report dated and filed on December 5, 1997 and incorporated herein by reference. 31

(21) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1997 on March 24, 1998 and incorporated herein by reference. (22) Filed as Exhibit 10.40 to the Guilford Pharmaceuticals Inc. Form 10-K for the year ended December 31, 1997 on March 27, 1998 and incorporated herein by reference. (23) Filed as an exhibit to the Form 10-Q for the quarter ended March 31, 1998 on May 13, 1998 and incorporated herein by reference. (24) Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1998 on August 14, 1998 and incorporated herein by reference. (25) Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 1998 on March 16, 1999 and incorporated herein by reference. (26) Filed as an exhibit to the Form 10-Q for the quarter ended June 30, 1999 on August 3, 1999 and incorporated herein by reference. 32

5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS CONTAINED IN THE COMPANY'S QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 1,000,000 9-MOS DEC-31-1999 JAN-01-1999 SEP-30-1999 188 1,336 326 26 147 2,126 2,230 721 4,037 818 223 0 0 0 2,995 4,037 2,195 2,413 290 290 580

0 10 1,181 366 815 0 0 0 815 0.80

0.76 ITEM CONSISTS OF RESEARCH AND DEVELOPMENT EXPENSES. REFLECTS A TWO-FOR-ONE SPLIT OF THE COMMON STOCK TO BE EFFECTED IN THE FORM OF A 100 PERCENT STOCK DIVIDEND TO BE DISTRIBUTED ON NOVEMBER 19, 1999 TO STOCKHOLDERS OF RECORD ON NOVEMBER 5, 1999. FINANCIAL DATA SCHEDULES FROM PRIOR PERIODS HAVE NOT BEEN RESTATED TO REFLECT THIS STOCK SPLIT.

EXHIBIT 99 AMGEN INC. Factors That May Affect Amgen Amgen operates in a rapidly changing environment that involves a number of risks, some of which are beyond our control. The following discussion highlights some of these risks and others are discussed elsewhere herein. Product development We intend to continue an aggressive product development program. Successful product development in the biotechnology industry is highly uncertain, and very few research and development projects produce a commercial product. Product candidates that appear promising in the early phases of development, such as in early human clinical trials, may fail to reach the market for a number of reasons, such as: - - the product candidate was not effective in treating a specified condition or illness - - the product candidate had harmful side effects on humans - - the necessary regulatory bodies (such as the FDA) did not approve our product candidate for an indicated use - - the product candidate was not economical for us to manufacture it - - other companies or people may have proprietary rights to our product candidate (e.g. patent rights) and will not let us sell it on reasonable terms, or at all - - the product candidate is not cost effective in light of existing therapeutics - - the product candidate did not demonstrate acceptable clinical trial results even though it demonstrated positive preclinical trial results For example, in 1997, we announced the failure of BDNF (for the treatment of ALS by subcutaneous injection administration route), because the product candidate, as administered, did not produce acceptable clinical results in a specific indication after a phase 3 trial, even though BDNF had progressed through preclinical and earlier clinical trials. Of course, there may be other factors that prevent us from marketing a product. We cannot guarantee we will be able to produce commercially successful products. Further, clinical trial results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others which may delay, limit or prevent further clinical development or regulatory approvals of a product candidate. Also, the length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied by product and by the indicated use of a product. We expect that this will likely be the case with future product candidates and we cannot predict the length of time to complete necessary clinical trials and obtain regulatory approval. See "- Regulatory matters." 1

Regulatory matters Our research, preclinical testing, clinical trials, facilities, manufacturing, pricing and sales and marketing are subject to extensive regulation by numerous state and federal governmental authorities in the U.S., such as the FDA and the Health Care Financing Administration ("HCFA"), as well as by foreign countries and the European Union (the "EU"). Currently, we are required in the U.S. and in foreign countries to obtain approval from those countries' regulatory authorities before we can market and sell our products in those countries. The success of our current and future products will depend in part upon obtaining and maintaining regulatory approval to market products in approved indications in the U.S. and foreign markets. In our experience, the regulatory approval process is a lengthy and complex process, both in the U.S. and in foreign countries, including countries in the EU. Even if we obtain regulatory approval, both our manufacturing processes and our marketed products are subject to continued review. Later discovery of previously unknown problems with our products or manufacturing processes may result in restrictions on such product or manufacturing processes, including withdrawal of the products from the market. Our failure to obtain necessary approvals, or the restriction, suspension or revocation of any approvals, or our failure to comply with regulatory requirements could prevent us from manufacturing or selling our products which could have a material adverse effect on us and our results of operations. Reimbursement; Third party payors In both domestic and foreign markets, sales of our products are dependent, in part, on the availability of reimbursement from third party payors such as state and federal governments (for example, under Medicare and Medicaid programs in the U.S.) and private insurance plans. In certain foreign markets, the pricing and profitability of our products generally are subject to government controls. In the U.S., there have been, and we expect there will continue to be, a number of state and federal proposals that limit the amount that state or federal governments will pay to reimburse the cost of drugs. In addition, we believe the increasing emphasis on managed care in the U.S. has and will continue to put pressure on the price and usage of our products, which may impact product sales. Further, when a new therapeutic is approved, the reimbursement status and rate of such a product is uncertain. In addition, current reimbursement policies for existing products may change at any time. Changes in reimbursement or our failure to obtain reimbursement for our products may reduce the demand for, or the price of, our products, which could result in lower product sales or revenues which could have a material adverse effect on us and our results of operations. For example, in the U.S. the use of EPOGEN(R) in connection with treatment for end stage renal disease is funded primarily by the U.S. federal government. Therefore, as in the past, EPOGEN(R) sales could be affected by future changes in reimbursement rates or the basis for reimbursement by the federal government. For example, in early 1997, HCFA instituted a reimbursement change for EPOGEN(R) which adversely affected the Company's EPOGEN(R) sales. See "Item 7. Management's Discussion and Analysis of Financial 2

Condition and Results of Operations - Results of Operations - Product sales - EPOGEN(R) (Epoetin alfa)." Guidelines Government agencies promulgate regulations and guidelines directly applicable to us and to our products. However, professional societies, practice management groups, private health/science foundations and organizations involved in various diseases may also publish, from time to time, guidelines or recommendations to the health care and patient communities. These organizations may make recommendations that affect a patient's usage of certain therapies, drugs or procedures, including our products. Recommendations of government agencies or these other groups/organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines that are followed by patients and health care providers could result in, among other things, decreased use of our products which could have a material adverse effect on our results of operations. In addition, the perception by the investment community or stockholders that such recommendations or guidelines will be followed could adversely affect prevailing market prices for our common stock. Intellectual property and legal matters The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and often involve complex legal, scientific and factual questions. To date, there has emerged no consistent policy regarding breadth of claims allowed in such companies' patents. Accordingly, the patents and patent applications relating to our products and technologies may be challenged, invalidated or circumvented by third parties and might not protect us against competitors with similar products or technology. Patent disputes are frequent and can preclude commercialization of products. We are currently, and in the future may be, involved in patent litigation. The results of such litigation could subject us to competition and/or significant liabilities, could require us to enter into third party licenses or could cause us to cease using the technology or product in dispute. In addition, we cannot guarantee that such licenses will be available on terms acceptable to us. The Company is currently involved in arbitration proceedings with Ortho Pharmaceutical Corporation (which has assigned its rights under the Product License Agreement to Ortho Biotech, Inc.), a subsidiary of Johnson & Johnson ("Johnson & Johnson"), relating to a license granted by the Company to Johnson & Johnson for sales of Epoetin alfa in the U.S. for all human uses except dialysis. See Note 4 to the Consolidated Financial Statements, "Contingencies - Johnson & Johnson arbitrations". Competition We operate in a highly competitive environment. Our principal competitors are pharmaceutical and biotechnology companies. Some of our competitors, mainly large pharmaceutical corporations, have greater clinical, research, regulatory and marketing resources than 3

we do. In addition, some of our competitors may have technical or competitive advantages over us for the development of technologies and processes and the acquisition of technology from academic institutions, government agencies and other private and public research organizations. We cannot guarantee that we will be able to produce or acquire rights to products that have commercial potential. Even if we achieve successful product commercialization, we cannot guarantee that one or more of our competitors will not achieve product commercialization earlier than we do, obtain patent protection that dominates or adversely affects our activities, or have significantly greater marketing capabilities. Fluctuations in operating results Our operating results may fluctuate from period to period for a number of reasons. In budgeting our operating expenses, some of which are fixed in the short term, we assume that revenues will continue to grow. Accordingly, even a relatively small revenue shortfall may cause a period's results to be below our expectations. A revenue shortfall could arise from any number of factors, such as: - - lower than expected demand for our products - - changes in the government's or private payor's reimbursement policies for our products - - changes in wholesaler buying patterns - - increased competition from new or existing products - - fluctuations in foreign currency exchange rates - - changes in our product pricing strategies Of course, there may be other factors that affect the Company's revenues in any given period. Rapid growth We have an aggressive growth plan that includes substantial and increasing investments in research and development and facilities. Our plan has a number of risks, such as: - - the need to generate higher revenues to cover a higher level of operating expenses - - the need to manage complexities associated with a larger and faster growing organization - - the need to accurately anticipate demand for the products we manufacture and maintain adequate manufacturing capacity Of course, there may be other risks and we cannot guarantee that we will be able to successfully manage these or other risks. Stock price volatility Our stock price, like that of other biotechnology companies, is extremely volatile. Our stock price may be affected by, among other things, clinical trial results and other product-development announcements by us or our competitors, regulatory matters, announcements in the scientific and research community, intellectual property and legal matters, changes in reimbursement policies or 4

medical practices or broader industry and market trends unrelated to our performance. In addition, if our revenues or earnings in any period fail to meet the investment community's expectations, there could be an immediate adverse impact on our stock price. 5